GlassScriptPhysician profile
Youngmi Lee
NPI 1659317329
$5,661.29
in general payments reported to CMS, 2019-2025
31 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,643 · 2022: $60.51 · 2023: $1,018 · 2024: $1,694 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,943 · Education: $14.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,943.45 |
| Education | $14.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.22 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $788.41 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $472.89 | 2021-2025 | Entyvio, Gattex |
| Janssen Scientific Affairs, LLC | $455.05 | 2021-2024 | Remicade, Stelara |
| Phathom Pharmaceuticals, INC. | $342.43 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $299.32 | 2021-2025 | Livdelzi, Vemlidy |
| Qol Medical, LLC | $266.98 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $233.42 | 2021-2024 | Tremfya, Stelara |
| Lilly USA, LLC | $163.17 | 2023-2025 | Jardiance, Omvoh, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $135.28 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $130.46 | 2021-2024 | Zeposia |
| Pfizer INC. | $122.90 | 2021-2025 | |
| Celgene Corporation | $121.33 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $94.82 | 2021 | |
| Braintree Laboratories, INC. | $66.21 | 2021-2025 | Suflave |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $65.02 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $57.07 | 2021-2023 | |
| Madrigal Pharmaceuticals | $51.60 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $42.61 | 2021-2025 | |
| Tersera Therapeutics LLC | $42.03 | 2021 | |
| Aimmune Therapeutics, INC. | $37.88 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $31.78 | 2024 | Vegzelma, Zymfentra |
| Vivus LLC | $30.02 | 2021 | |
| Enterra Medical, INC. | $29.78 | 2024 | |
| Redhill Biopharma INC. | $28.89 | 2022-2024 | Talicia |
| Ipsen Biopharmaceuticals, INC | $21.73 | 2025 | Iqirvo |
| Cranial Technologies, INC | $19.04 | 2023 | Doc Band |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.41 | 2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $15.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.31 | 2023 | Breztri |
| Ferring Pharmaceuticals INC. | $14.79 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youngmi Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.